FMA
VIVO

FNY Managed Accounts’s Meridian Bioscience Inc VIVO Stock Holding History

FNY Managed Accounts’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$2K Buy
+199
New +$2.94K ﹤0.01% 453
2017
Q3 		– Sell
-951
Closed -$14K – 706
2017
Q2 		$14K Sell
951
-344
-27% -$4.96K 0.14% 113
2017
Q1 		$17K Buy
+1,295
New +$18.1K 0.05% 392

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FNY Managed Accounts's VIVO Position: Q1 2018 in Review

FNY Managed Accounts opened a new position in Meridian Bioscience Inc (VIVO) in Q1 2018: 199 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #453 among its holdings. This is a return to the name: FNY Managed Accounts previously reported a position in VIVO as recently as Q2 2017.

FNY Managed Accounts first reported a position in VIVO in Q1 2017 and has held it in 3 quarters since. The position peaked at $17K in Q1 2017. 186 funds tracked by Wall St. Rank hold VIVO as of Q1 2018.

  • FNY Managed Accounts held 199 shares of Meridian Bioscience Inc worth $2K as of Q1 2018.
  • Meridian Bioscience Inc was a new FNY Managed Accounts position in Q1 2018.
  • Meridian Bioscience Inc made up ﹤0.01% of FNY Managed Accounts's portfolio in Q1 2018, its #453 holding.
  • FNY Managed Accounts first reported a position in Meridian Bioscience Inc in Q1 2017 and has held it in 3 quarters since.
  • FNY Managed Accounts's Meridian Bioscience Inc position peaked at $17K in Q1 2017.
  • 186 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.